Nature's Sunshine Aims High: Vision for Growth Targets $1B as China Stumbles and Leadership Turns

The direct-selling vitamin maker doubles down on digital, new markets, and fresh faces, even as a China slowdown forces a guidance cut and the stock falls to a drawdown.

NATR · Earnings Call · 2026-08-06

A Quarter of Mixed Signals

Nature's Sunshine Products (NASDAQ: NATR) reported a solid Q2 on the surface, but the market's reaction—the stock is down nearly 47% over the past 90 days—tells a more nuanced story. CEO Kenneth Romanzi opened the call with a confident tone: “we delivered a solid second quarter, growing sales 4% in constant currency” — Kenneth Romanzi, Chief Executive Officer · 2026-08-06, and CFO (acting) Jon Lanoy added that net sales reached “$117 million, representing our strongest second quarter in company history” — Jonathan Lanoy, Chief Accounting Officer · 2026-08-06. Yet the company simultaneously slashed its full-year guidance, citing China weakness and FX headwinds—a classic case of a miss embedded in an apparent beat. The direct selling channel, long the company's core, has been soft for years. Growth is increasingly coming from digital channels, where North American digital sales jumped 26% and autoship subscriptions now account for 36% of website orders. The company is betting heavily on this shift, but the china stumble reveals fragility in its Asia engine.

China: The Reversal

The most striking negative in the quarter was China, which declined 20% year-over-year after growing over 30% for the past year. Lanoy attributed the reversal to "a few operational issues" but insisted the problems are "short term in nature." This is a sharp departure from the prior quarter's narrative—in May, CFO Shane Jones had praised “economic stabilization” — Shane Jones, Chief Financial Officer · 2025-11-06 in China and strong demand, making the sudden drop a credibility test. The company cut its net sales guidance from $500–515M to $490–500M, and EBITDA from $50–54M to $48–52M, explicitly flagging China. The market clearly priced in a deeper problem, as the stock now sits 48% below its March peak. The customer acquisition engine, once a source of optimism, is now intertwined with the China issue. Still, management insists the long-term opportunity remains intact, pointing to the company's brand strength and the broader health-supplement market.

Vision for Growth: New Blueprint, New Faces

The call's centerpiece was the formal unveiling of Vision for Growth—a plan to double sales to $1 billion and lift EBITDA margin to 15% from just above 10%. Romanzi laid out four growth drivers: digital expansion, geographic penetration, superior product innovation, and M&A. He also announced two high-profile hires: Ruth Perkins as CFO (from Estée Lauder and PepsiCo) and Janine Weber as President of North America (a direct-selling veteran who helped Rodan + Fields reach $1B).

We have set long-term goals for our Vision for Growth to double the size of the company to $1 billion in sales and improve our EBITDA margin to 15% from its currently just north of 10%.
Kenneth Romanzi, Chief Executive Officer · 2026-08-06

This is not the first time the $1B target has been mentioned—Romanzi teased it in March—but the current call marks the first time it appears as a formal, quantified strategic plan with named leaders. The new CFO's supply-chain finance background is telling: Gross margin expanded ~200 bps to 73.7% in Q2, management's highest in over four years, and they guide to low-to-mid 73% for the rest of the year. That supports the margin-expansion pillar of the plan.

Digital and Direct: The Two-Lane Strategy

In North America, the company is pursuing a dual approach: keep driving the independent consultant network while scaling the direct-to-consumer digital business. Digital is on track to hit $50M this year, just five years after launch. Social commerce is exploding, with subscription autoship making up 60% of that channel's revenue. Romanzi stated that the lifetime value of autoship customers is more than 3x higher than non-subscribers—a critical metric for justifying continued marketing spend. At the same time, management acknowledged the core direct selling business has been "under pressure for quite some time" and announced a full reinvigoration planned for early 2027, including a new compensation plan and incentives. This two-lane strategy is risky—cannibalization is a real concern—but the company argues it can serve both customer types with differentiated products.

Geographic Ambitions and M&A

[Germany] launched earlier this year, and management is recruiting heavily: “we are recruiting leaders as we speak. I think we're bringing on 150 consultants a month there right now” — Kenneth Romanzi, Chief Executive Officer · 2026-08-06. A Berlin summit drew 400 prospective consultants. The company also plans to open a new Asian country (likely via Synergy's system) in 2027, and it will treat the U.S. as a "new country" for Synergy expansion. M&A is the fourth driver, but Romanzi emphasized selectivity: products must fit its manufacturing capacity, be in supplements, and preferably add channel or geographic diversification. He noted the company has excess factory capacity, so bolt-on deals could be immediately accretive. This is a patient, disciplined approach—but with the stock trading at a 47% drawdown, valuation may start to attract interest.

The Tape and The Table

The stock's -47% drawdown over 90 days is the loudest signal. While the company beat its own guidance, the cut, combined with China's reversal and a CEO transition (Shane Jones departed in June) creates an air of uncertainty. Yet the fundamentals remain sound: Total revenue reached $123M in Q1, up 9% YoY, with a clean balance sheet. The EBITDA margin is still in the low-double digits, but the path to 15% is plausible if digital mix and manufacturing utilization continue to improve. For now, Nature's Sunshine is a story of strategic reinvention under duress. The Vision for Growth is ambitious, and the leadership shake-up brings fresh skills, but execution—especially in China—will determine whether the stock's slide reverses or continues.